Descriptive aspects of injection drug users in Iran's national harm reduction program by methadone maintenance treatment

Iranian Journal of Public Health

Volumn 42, Issue 6, 2013, Pages 588-593

  Eskandarieh, Sharareh ^a   Nikfarjam, Ali ^a   Tarjoman, Termeh ^a   Nasehi, Abassali ^a   Jafari, Firoozeh ^b   Saberi Zafarg Handi, Mohammad Bagher ^c  

^a MINISTRY OF HEALTH AND MEDICAL EDUCATION   (Iran)

^b UNIVERSITY OF SOCIAL WELFARE AND REHABILITATION SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Harm reduction; IDUs; Iran; Methadone maintenance treatment

Indexed keywords

EID: 84886912474     PISSN: 22516085     EISSN: 22516093     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Hazel W, Alison M, Marsha W, Susan K, Jon G (2010). World Health Organization. The involvement of nurses and midwives in screening and brief interventions for hazardous and harmful use of alcohol and other psychoactive substances. Available from: http://www.who.int/hrh/resources/sub-stances/en/index.html
2. Gheiratmand R, Navipour R, Mohebbi MR, Mallik AK (2005). Uncertainty on the number of HIV/AIDS patients: our experience in Iran. Sex Transm Infect, 81: 279-280.
3. Razzaghi E, Movaghar A, Green T, Khoshnood K (2006). Profiles of risk: a qualitative study of injecting drug users in Tehran, Iran. Harm Reduct J, 3.
4. Shafer KP, Hahn JA, Lum PJ (2002). Prevalence and correlates of HIV infection among young injection drug users in San Francisco. JAIDS, 31: 422-431.
5. Monga HK, Rodrguez-Barradas MC, Breaux K (2001). Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection. Clin Infect Dis, 33: 240 247.
6. Falstar K, Kaldor JM, Maher L (2009). Hepatitis C acquisition among injection drug users: a cohort analysis of a national repeated cross-sectional survey of needle and syringe program attendees in Australia 1995-2004. J Urban Health, 86 (1): 106-18.
7. Prejean J, Song R, Hernandez A, Ziebell R, Green T, Walker F, Lin LS, An Q, Mermin J, Lansky A, Hall HI (2011). Estimated HIV incidence in the United States, 2006-2009. PLoS One, 6(8):e17502.
8. Hafeiz HB (1995). Socio-demographic correlates and pattern of drug abuse in eastern Saudi Arabia. Drug Alcohol Depend, 38 (3): 255-259.
9. Yen YF, Yen MY, Su LW, Li LH, Chuang P, Jiang XR, Deng CY (2012). Prevalences and associated risk factors of HCV/HIV co-infection and HCV mono-infection among injecting drug users in a methadone maintenance treatment program, Taiwan. BMC Public Health, 12:1066.
10. Zhou YH, Yao ZH, Liu FL, Li H, Jiang L, Zhu JW, Zheng YT (2012). High prevalence of HIV, HCV, HBV and co-infection and associated risk factors among injecting drug users in Yunnan province, China. PLoS One, 7(8):e42937.
11. Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D, Degenhardt L (2011). Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet, 378(9791):571.
12. Centers for Disease Control and Prevention (CDC) (2012). HIV infection and HIV-associated behaviors among injecting drug users - 20 cities, United States, 2009. MMWR Morb Mortal Wkly Rep, 61(8):133-8.
13. King VL, Stoller KB, Hayes M (2002). A multicen-ter randomized evaluation of methadone medical maintenance. Drug Alcohol Depend, 65: 137-48.
14. Marsch L (1998). The efficacy of methadone maintenance interventions in reducing illicit opiate use, HIV risk behavior and criminality. Addiction, 93: 515-32.
15. Ward J, Hall W, Mattick RP (1999). Role of maintenance treatment in opioid dependence. Lancet, 353: 221-6.
16. Gossop M, Morsden J, Stewart D, (2002). Reduced injection risk and sexual risk behaviors after drug misuse treatment: results from the National Treatment Outcome Research Study. AIDS Care, 14: 77-93.
17. Thirion X, Micallef J, Barrau K (2001). Recent evolution in opiate dependence in France during generalisation of maintenance treatments. Drug Alcohol Depend, 61: 281-5.
18. Aghaee-Afshar M, Khazaeli P, Behzad, Zadehkermani M, Ganjooei N, (2008). Presence of lead in opium. Arch Iran Med, 11(5): 553-554.
19. Kheirandish P, SeyedAlinaghi S, Jahani M, Shirzad H, Seyed Ahmadian M, Majidi A, et al (2009). Prevalence and Correlates of Hepatitis C Infection among Male Injection Drug Users in Detention, Tehran, Iran. J Urban Health, 86 (6): 902-8.
20. Razani N, Mohraz M, Kheirandish P, Malekinejad M, Malekafzali H, Mokri A, et al (2007). HIV risk behavior among injection drug users in Tehran, Iran. Addiction, 102 (9): 1472-82.
21. Hosseini M, SeyedAlinaghi S, Kheirandish P, Esmaeli G, Shirzad H, Karami N, et al (2010). Correlates of Co-infection with Human Immu-node_ciency Virus and Hepatitis C Virus in Male Injection Drug Users in Iran. Arch Iran Med, 13(4): 318-23.
22. Vahdani P, Hosseini-Moghaddam M, Family A, Moheb-Dezfouli R (2009). Prevalence of HBV, HCV, HIV, and Syphilis among Homeless Subjects Older than Fifteen Years in Tehran. Arch Iran Med, 12 (5): 483-487.
23. Davoodian P, Dadvand H, Mahoori K, Amoozandeh A, Salavati A (2009). Prevalence of Selected Sexually and Blood-Borne Infections in Injecting Drug Abuser Inmates of Bandar Abbas and Roodan Correction Facilities, Iran. Braz J Infect Dis, 13(5): 356-8.
24. Shah NG, Galai N, Celentano DD, Vlahov D, Strathdee SA (2006). Longitudinal predictors of injection cessation and subsequent relapse among a cohort of injection drug users in Baltimore, MD, 1988-2000, Drug Alcohol Depend, 83(2):147-56.
25. Salimi S, Nassirimanesh B, Mohsenifar S, Mokri A, Dolan K (2011). The establishment of a me-thadone treatment clinic for women in Tehran, Iran. J Public Health Policy. 32 (2): 219-30.
26. UNDCP (1999). A Rapid Situation Assessment of Drug Abuse in Iran. Available from: http://www.unrol.org/files/RSA200MARY[1].
27. Prejean J, Song R, Hernandez A, Ziebell R, Green T, Walker F, Lin LS, et al (2011). Estimated HIV incidence in the United States, 2006-2009. PLoS One, 6 (8): e17502.
28. Jennifer L, Judith A., Kimberly P, Paula J, Ellen S, Peter J, et al (2003). Gender Differences in Sexual and Injection Risk Behavior Among Active Young Injection Drug Users in San Francisco. J Urban Health, 80 (1): 137-46.
29. Doherty MC, Garfein RS, Monterroso E, Latkin C, Vlahov D (2000). Gender differences in the initiation of injection drug use among young adults, J Urban Health, 77: 396-414.
30. Rudolph AE, Crawford ND, Latkin C, White K, Benjamin EO, Jones K, Fuller CM (2011). Individual, study, and neighborhood level characteristics associated with peer recruitment of young illicit drug users in New York City: optimizing respondent driven sampling. Soc Sci Med, 73 (7): 1097-104.
31. Galea S, Vlahov D (2002). Social determinants and the health of drug users: socioeconomic status, homelessness, and incarceration. Public Health Rep, 117 (1): 135-45.
32. Rafiey H, Narenjiha H, Shirinbayan P, Noori R, Javadipour M, Roshanpajouh M, et al (2009). Needle and syringe sharing among Iranian drug injectors. Harm Reduct J, 30 (6): 21-31
33. Rowhani Rahbar A, Rooholamini S, Khoshnood K (2004). Prevalence of HIV infection and other blood-borne infections in incarcerated and non-incarcerated injection drug users (IDUS) in Mashhad, Iran. Int J Drug Policy, 15: 151-155.
34. Mohammad Ali Zadeh AH, Alavian SM, Jafari K, et al (2003). Prevalence of HBS AG, HC AB & HIVAB in the addict prisoners of Hammadan prison (Iran, 1998). JRMS, 7(4): 311-313.
35. Mathers BM, Degenhardt L, Ali H, et al (2010). HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage. Lancet, 375:1014-28.
36. Rahimi-Movaghar A, Razaghi EM, Sahimi-Izadian E, Amin-Esmaeili M. HIV (2010). hepatitis C virus, and hepatitis B virus co-infections among injection drug users in Tehran, Iran. Int J Infect Dis, 14 (1): 28-33.
37. Rinken S, Vallecillo O (2002). The evolution of Spanish HIV prevention policy targeted at opiate users: a review. DRUG-EDUC PREV POLIC, 9: 45-56.
38. Mojtahedzadeh V, Razani N, Malekinejad M, Vazirian M, Shoaee S, Saberi Zafarghandi MB, et al (2008). Injection drug use in Rural Iran: integrating HIV prevention into iran's rural primary health care system. AIDS Behav, 12(4): 7.
39. McDonald SA, Hutchinson SJ, Wallace LA, Cameron SO, Templeton K, McIntyre P, et al (2011). Trends in the incidence of HIV in Scotland, 1988-2009. Sex Transm Infect. Dec 8.
40. Smye V, Browne AJ, Varcoe C, Josewski V (2011). Harm reduction, methadone maintenance treatment and the root causes of health and social inequities: An intersectional lens in the Canadian context. Harm Reduct J, 8 (1): 17.